In Vivo CRISPR: The 2026 Mass Medical Scaling That Ends Genetic Disease

2026 marks the pivotal transition of in vivo CRISPR gene editing from a single, artisanal case to a broad clinical reality, fundamentally altering the economic model of healthcare by replacing chronic management with curative, one-time interventions for ultra-rare and aggressive diseases. This systemic shift converges genetic engineering with AI-driven research agents and circular economy principles, creating a dual benefit of eradicating untreatable genetic conditions while valorizing waste through engineered microorganisms. The year also parallels historic space milestones like Artemis II and Chang'e-7, signaling a global re-establishment of permanent presence on the Moon alongside the internal curing of biological vulnerabilities.